Trials / Recruiting
RecruitingNCT05421416
Loratadine for the Prevention of G-CSF-related Bone Pain
Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Loratadine | Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors. |
| DRUG | Placebo | Placebo sugar pill |
Timeline
- Start date
- 2024-11-28
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2022-06-16
- Last updated
- 2026-02-05
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05421416. Inclusion in this directory is not an endorsement.